This study is testing a new treatment called Afimkibart for people with Crohn's disease (CD), which is a condition causing inflammation in the digestive tract. The study is double-blind, meaning neither the participants nor the researchers know who is receiving Afimkibart and who is receiving a placebo, which is a substance with no active ingredient, to ensure fair results. Participants need to have moderate to severe CD and must have tried at least one other treatment without success.

• The study involves multiple centers, which means several locations are participating.
• Participants should expect several visits over the course of the study.
• There are specific health criteria to join the study, like body weight and previous treatments.

If you are considering joining, it's important to understand the study may have risks, like any medical trial, and you should discuss this with a healthcare professional. Participants cannot currently be pregnant, breastfeeding, or have certain other health conditions like infections or other types of colitis (another form of bowel disease).